Lotus Pharmaceuticals Inc. (OTC BB: LTUS) is becoming one of China’s leaders in the marketing of prescription and over the counter medications. Lotus develops high quality, low cost generic medication and other over the counter brands. Led by their CEO Dr. Liu Zhongyi, the company expects to have continued growth of 20% per year and yearly revenues of over $140 million. For further information, visit the company website at: www.lotuseast.com.
- 17 years ago
QualityStocks
Lotus Pharmaceuticals Inc. (OTC BB: LTUS)
Tags Rodman & Renshaw
Related Post
-
Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Year-End Report Shows Alignment with Domestic Resource Priorities, Strong Strategic Positioning
Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include…
-
CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) to Execute Comprehensive Exploration Plan Focused on Promising Potential of Multiple Additional Silver-Bearing Veins
Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may…
-
Scaling Care, Tightening Controls: How Earth Science Tech Inc. (ETST) Is Building a Multi-Unit Healthcare Platform
Earth Science Tech reported fiscal Q3 2026 revenue of $8.4 million, up 14.1% year over…